ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 088,24
0,89%
Dow Jones
38 239,66
0,40%
DAX
18 161,01
1,32%
Brent Oil
88,165
0,00%
Bitcoin
63 519,03
0,17%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. ALX Oncology Holdings Inc (ALXO)

  7. ALX Oncology Holdings Inc (ALXO) Actualités

ALXO ALX Oncology Holdings Inc

16,86
-0,01 (-0,06%)
26 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
ALX Oncology Holdings Inc ALXO NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,01 -0,06% 16,86 22:58:36
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
16,81 16,54 17,37 16,86 16,87
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
24/4/202416:00GLOBEALX Oncology Announces Two Evorpacept Abstracts Accepted for..
09/4/202423:30GLOBEALX Oncology Reports Encouraging Clinical Data of Evorpacept..
07/3/202422:05EDGAR2Form 8-K - Current report
07/3/202422:03GLOBEALX Oncology Reports Fourth Quarter and Full Year 2023..
05/3/202422:30GLOBEALX Oncology Announces Two Evorpacept Clinical Abstracts..
17/2/202400:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/2/202400:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/2/202400:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202422:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202422:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202422:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202414:00GLOBEALX Oncology to Present at the 42nd Annual J.P. Morgan..
26/12/202322:01EDGAR2Form 8-K - Current report
13/11/202322:05GLOBEALX Oncology Reports Third Quarter 2023 Financial Results..
13/11/202322:03EDGAR2Form 8-K - Current report
01/11/202321:05GLOBEALX Oncology Announces November Investor Conference..
10/10/202322:05GLOBEALX Oncology Announces Closing of Public Offering, Including..
06/10/202312:06EDGAR2Form 8-K - Current report
06/10/202312:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/10/202314:00GLOBEALX Oncology Announces Pricing of Public Offering
04/10/202323:21EDGAR2Form 8-K - Current report
04/10/202323:21EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04/10/202322:10GLOBEALX Oncology Announces Proposed Public Offering
04/10/202314:00EDGAR2Form 8-K - Current report
03/10/202316:03IHMARKETNEWSKeep An Eye Out: Pre-Market Movers And Recommendations
03/10/202312:00GLOBEALX Oncology Reports Positive Interim Phase 2 ASPEN-06..
02/10/202322:05GLOBEALX Oncology to Host Investor Call and Webcast on October 3,..
20/9/202314:45IHNWPathways to Progress: How Orphan Drug Designation Sparks..
11/9/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
08/9/202322:25EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
06/9/202322:05EDGAR2Form 8-K - Current report
06/9/202314:00GLOBEALX Oncology Realigns Executive Leadership Team
01/9/202322:11EDGAR2Form S-3 - Registration statement under Securities Act of..
31/8/202313:00GLOBEALX Oncology Announces September Investor Conference..
25/8/202322:44EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
10/8/202322:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202322:05EDGAR2Form 8-K - Current report
10/8/202322:01GLOBEALX Oncology Reports Second Quarter 2023 Financial Results..
27/7/202322:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/7/202322:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/7/202322:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/7/202322:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/7/202323:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/7/202323:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/7/202323:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/6/202313:00GLOBEALX Oncology Receives Orphan Drug Designation from the..
11/5/202322:01GLOBEALX Oncology Reports First Quarter 2023 Financial Results..
09/5/202313:00GLOBEALX Oncology Announces First Patient Dosed in Phase 2..

Dernières Valeurs Consultées

NASDAQ
ALXO
ALX Oncology
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés